Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study

Yang Yuan¹, Shaohua Zhang¹, Min Yan², Yongmei Yin³, Yuhua Song⁴, Zefei Jiang¹

¹Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China; ²Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; ³Department of Breast Cancer, Jiangsu Province Hospital & The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ⁴Department of Breast Cancer Center, The Affiliated Hospital of Qingdao University, Qingdao, China

Contributions: (I) Conception and design: Z Jiang; (II) Administrative support: S Zhang, Z Jiang; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Y Yuan, S Zhang, M Yan, Y Yin, Y Song; (V) Data analysis and interpretation: Y Yuan, S Zhang, Z Jiang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Shaohua Zhang. Department of Breast Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, No. 8 East Street, Fentai District, Beijing 100071, China. Email: zhangsh19760428@163.com.

Background: Although endocrine therapy (ET) is the preferred option for hormone receptor-positive HER2-negative metastatic breast cancer (HR+/HER2– MBC), chemotherapy (CT) is still commonly used. The objective of this real-world study was to present the actual choice of first-line treatment for patients with HR+/HER2– MBC and evaluate the consistency with guidelines in China.

Methods: Patients with HR+/HER2– MBC between 1996 and September 2018 were identified from the database of Chinese Society of Clinical Oncology Breast Cancer (CSCO BC). The statistical description was conducted to present the first-line treatment. Factors influencing the prescription of ET or CT were obtained using univariate and multivariate analysis. The consistency of the actual treatment with the guideline of Chinese Society of Clinical Oncology Breast Cancer (CSCO BC guideline) was evaluated.

Results: Of 1,877 patients, 662 (35.3%) received ET, and 1,215 (64.7%) received CT. ET proportion was only 25.4% in 1996–2005 and gradually increased to 44.6% in 2016–2018. Aromatase inhibitors (69% of ET) and taxane-based regimens (66% of CT) were the most commonly used ET and CT, respectively. Univariate and multivariate analysis showed that patients with age ≥60, distant relapse-free interval (DRFI) ≥24 months, ER+/PR+, bone metastasis only, or progression on (neo)adjuvant ET were preferably chosen for ET as first-line treatment. Factors associated with preferring CT were de novo stage IV, liver or lung metastasis. 17.2% of patients (322 cases) who had neither visceral metastasis nor progression on (neo)adjuvant ET wrongly received CT instead of ET, which is inconsistent with CSCO BC guideline. More than half of patients receiving CT discontinued their initial treatment due to adverse events and other non-disease progression reasons.

Conclusions: Although high proportion of HR+/HER2– MBC patients received CT as first-line treatment in China, it is gratifying to see that the proportion of patients receiving ET has gradually increased. Our study revealed that 17.2% of patients were over-treated according to CSCO BC guideline, which may provide data to promote guideline adherence. The clinical application for ET should be appropriately expanded in first-line treatment, especially for patients without visceral disease and proof of endocrine resistance.

Keywords: Metastatic breast cancer (MBC); hormone receptor-positive; chemotherapy (CT); endocrine therapy (ET); guideline

Submitted Dec 31, 2020. Accepted for publication Mar 28, 2021.
doi: 10.21037/atm-20-8252
View this article at: http://dx.doi.org/10.21037/atm-20-8252
Introduction

Breast cancer (BC) is the most common malignancy, and the fifth leading cause of death among women in China (1). The primary cause of BC-associated death is metastasis. Hormone receptor-positive HER2-negative (HR+/HER2–) BC accounts for approximately 65% of all metastatic breast cancer (MBC) (2). MBC is incurable, and the purpose of its treatment is mainly to prolong patient survival while maintaining or improving the quality of life (3,4). Receiving appropriate anti-tumor treatment is essential to achieve these goals.

According to international (5-7) and domestic guidelines (8), endocrine therapy (ET) is the preferred therapeutic option for HR+/HER2– MBC, even in the presence of visceral disease, unless there is a visceral crisis or concern/proof of endocrine resistance. However, chemotherapy (CT) is commonly used in clinical practice. In the past decade, randomized controlled trials (RCTs) (9-14) have led to introducing several innovative therapeutic strategies into clinical practice, consisting of single-agent ET and new targeted drugs combined with ET. Real-world knowledge of treatment patterns in patients with HR+/HER2– MBC is urgently needed in improving clinical practice.

Retrospective reports from European countries (15-19) and the United States (20) showed differences in initial treatment options for HR+/HER2– MBC among countries. There is a lack of overview on first-line treatment in Chinese population. Therefore, we carried out a real-world study in a large, multicenter cohort of patients with HR+/HER2– MBC from the database of Chinese Society of Clinical Oncology Breast Cancer (CSCO BC).

The study’s main purpose is to describe the first-line treatment choices being made in clinical practice and evaluate their consistency with the guideline of Chinese Society of Clinical Oncology Breast Cancer (CSCO BC). We present the following article in accordance with the STROBE reporting checklist (available at http://dx.doi.org/10.21037/atm-20-8252).

Methods

Study design

This study was conducted using a retrospective cohort design. Patients with HR+/HER2– MBC between 1996 and September 2018 were identified from the database of CSCO BC, which is derived from nine hospitals’ inpatient and outpatient medical records across seven cities in China. The last follow-up date was September 30, 2019.

Patients and data collection

Patients with HR-positive HER2-negative metastasis disease were eligible for inclusion. The inclusion criteria were either primary or metastatic tumor that expressed estrogen or progesterone receptors in at least 10% of cells before first-line treatment, as assessed with the use of immunohistochemistry testing. Patients had received first-line systemic treatment, efficacy evaluation, or safety evaluation at least once. The exclusion criteria were as follows: HER2-positive MBC before first-line systemic treatment, missing information of first-line treatment, regional recurrence only, that had been removed by surgery or radiotherapy. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics board of The Affiliated Hospital of Qingdao University (No. 221311920). Because of the retrospective nature of the research, the requirement for informed consent was waived.

We collected data on patient demography, clinical and pathological status, first-line treatment, efficacy and safety evaluation, and subsequent administration after drug withdrawal of initial first-line treatment from medical records. ET was defined as single-agent ET or ET plus targeted drugs. Similarly, CT was defined as single-agent CT or combination of CT (or combination of CT and targeted drugs). The patients were followed up by routine medical visit, or telephone calls with patients or their families.

Distant relapse-free interval (DRFI) was defined as the time from diagnosis of breast cancer to relapse at a distant site, and prior (neo)adjuvant ET disease-free interval was defined as the time from the end of (neo)adjuvant ET to relapse. Progression on (neo)adjuvant ET was defined as prior (neo)adjuvant ET disease-free interval ≤12 months. The reasons for drug withdrawal due to non-disease progression were adverse events, completion of the planned treatment, and patients’ personal reasons.

Assessment

The proportion of CT and ET as first-line treatment was statistically analyzed within four time periods of 1996–2005, 2006–2010, 2011–2015, and 2016–2018. The following objective variables were assessed in influencing the choice
of first-line treatment in MBC patients: age (≥60 years old vs. <60), comorbidity (yes vs. no), HR status (ER+/PR+ vs. ER+/PR− and ER−/PR+), metastatic status (de novo stage IV vs. recurrent metastasis), DRFI (≥24 vs. <24 m), progression on (neo)adjuvant ET (yes vs. no), number of metastatic sites (≥2 vs. 1), visceral involvement (yes vs. no), bone metastasis only (yes vs. no), liver metastasis (yes vs. no), and lung metastasis (yes vs. no).

According to the CSCO BC guideline, patients who had neither visceral disease nor progression on previous (neo) adjuvant ET should receive ET as initial systemic therapy. If these patients received CT instead of ET, it is considered inconsistency with guideline.

Statistical analysis

Disease characteristics, the proportion of CT and ET within four time periods, first-line treatment regimens, reasons for drug withdrawal, and the subsequent administration after drug withdrawal of initial first-line treatment were summarized through descriptive analysis. Factors influencing CT vs. ET prescription were investigated through univariate and multivariate logistic regression with odds ratio (OR) calculation.

Results

Baseline characteristics and factors influencing the prescription of CT or ET

A total of 2,325 HR+/HER2− MBC patients were identified, of which 448 were excluded due to hormone receptor-positive expression less than 10%, missing information of the first-line treatment, follow-up less than once, or regional recurrence which had been removed by surgery or radiotherapy. Finally, 1,877 cases were analyzed (Figure 1).

The baseline characteristics of patients are summarized in Table 1. The median age at first diagnosis of MBC was 48-year, de novo stage IV accounts for 11.8% of all patients. For patients with recurrent MBC (1,655, 88.2%), the median DRFI was 65 months. The most common site of metastasis was bone (52.9%), followed by lung (32.6%) and liver (20.2%). Overall, 909 patients (48.4%) had visceral metastases, 1,525 patients (81.2%) had received (neo) adjuvant CT, and 1,283 patients (68.4%) had received (neo) adjuvant ET. Missing data was recorded in Table 1.
### Table 1 Baseline characteristics

|                          | ALL (n=1,877) | CT (n=1,215) | ET (n=662) |
|--------------------------|---------------|--------------|------------|
| **Gender**               |               |              |            |
| Female                   | 1,861 (99.1)  | 1,202 (98.9) | 659 (99.5) |
| Male                     | 16 (0.9)      | 13 (1.1)     | 3 (0.5)    |
| **Age, years**           |               |              |            |
| Median (min; max)        | 48 (22; 83)   | 47 (23; 79)  | 49 (22; 83)|
| <60                      | 1,598 (85.1)  | 1,073 (88.3) | 525 (79.3)|
| ≥60                      | 279 (14.9)    | 142 (11.7)   | 137 (20.7)|
| **HR status**            |               |              |            |
| ER+/PR+                  | 1,427 (76.0)  | 871 (71.7)   | 556 (84.0)|
| ER+/PR–                  | 344 (18.3)    | 249 (20.5)   | 95 (14.4)|
| ER–/PR+                  | 106 (5.6)     | 95 (7.8)     | 11 (1.7)|
| **Distant relapse-free interval** |         |              |            |
| *De novo* stage IV       | 222 (11.8)    | 197 (16.2)   | 25 (3.8) |
| <24 m                    | 445 (23.7)    | 299 (24.6)   | 146 (22.1)|
| ≥24 m                    | 1,210 (64.5)  | 719 (59.2)   | 491 (74.2)|
| **Number of metastatic sites** |       |              |            |
| 1                        | 931 (49.6)    | 534 (44.0)   | 397 (60.0)|
| ≥2                       | 946 (50.4)    | 681 (56.0)   | 265 (40.0)|
| **Visceral disease**     |               |              |            |
| No                       | 968 (51.6)    | 569 (46.8)   | 399 (60.3)|
| Yes                      | 909 (48.4)    | 646 (53.2)   | 263 (39.7)|
| **Metastasis site**      |               |              |            |
| Bone only                | 390 (20.8)    | 181 (14.9)   | 209 (31.6)|
| Bone                     | 993 (52.9)    | 603 (49.6)   | 390 (58.9)|
| Liver                    | 379 (20.2)    | 294 (24.2)   | 85 (12.8)|
| Lung                     | 611 (32.6)    | 426 (35.1)   | 185 (27.9)|
| Brain                    | 59 (3.1)      | 37 (3.0)     | 22 (3.3)|
| **Prior (neo)adjuvant ET disease-free interval**<sup>a</sup> | | | |
| ET naïve                 | 586 (31.2)    | 457 (37.6)   | 129 (19.5)|
| >12 m                    | 321 (17.1)    | 186 (15.3)   | 135 (20.4)|
| ≤12 m                    | 965 (51.4)    | 568 (46.7)   | 397 (60.0)|
| **(Neo)adjuvant ET**<sup>b</sup> | | | |
| No                       | 587 (31.3)    | 457 (37.6)   | 130 (19.6)|
| SERMs<sup>c</sup>        | 1,051 (56.0)  | 623 (51.3)   | 428 (64.7)|
| AIs                      | 361 (19.2)    | 206 (17.0)   | 155 (23.4)|

*Table 1 (continued)*
Table 1 (continued)

|                          | ALL (n=1,877) | CT (n=1,215) | ET (n=662) |
|--------------------------|--------------|--------------|------------|
| (Neo)adjuvant CT<sup>c</sup> |              |              |            |
| No                       | 328 (17.5)   | 255 (21.0)   | 73 (11.0)  |
| Yes                      | 1,525 (81.2) | 941 (77.4)   | 584 (88.2) |
| Comorbidity<sup>e</sup>  |              |              |            |
| No                       | 403 (21.5)   | 240 (19.8)   | 163 (24.6) |
| Hypertension             | 192 (10.2)   | 115 (9.5)    | 77 (11.6)  |
| Diabetes                 | 110 (5.9)    | 65 (5.3)     | 45 (6.8)   |
| Cardiac and brain diseases | 60 (3.2)    | 31 (2.6)     | 29 (4.4)   |
| Liver diseases           | 67 (3.6)     | 41 (3.4)     | 26 (3.9)   |
| Other malignancy         | 12 (0.6)     | 6 (0.5)      | 6 (0.9)    |
| Other systemic diseases  | 78 (4.2)     | 38 (3.1)     | 40 (6.0)   |

Data were presented as n (%).<sup>a</sup>, 5 missing; <sup>b</sup>, 7 missing; <sup>c</sup>, 129 patients received both SERMs and AIs as (neo)adjuvant therapy; <sup>d</sup>, 24 missing; <sup>e</sup>, comorbidity refers to the systemic diseases that were diagnosed before first-line treatment; other systemic diseases include kidney disease, blood system, immune system, and mental illness.

Univariate and multivariate analysis of factors influencing the prescription of CT vs. ET is shown in Table 2. In patients with age ≥60 y, DRFI ≥24 months, ER+/PR+, bone metastasis only, or progression on (neo)adjuvant ET, ET was preferred as the first-line treatment. Factors associated with preferring CT were de novo stage IV, liver or lung metastasis.

The proportion of initial CT and ET in HR+/HER2–MBC patients with different clinical characteristics is shown in Table 3 and Figure S1. Among patients who had neither visceral disease nor progression on previous (neo)adjuvant ET, 322 patients (17.2% of total patients) received CT as initial systemic treatment. Meanwhile, 146 patients (7.8% of total patients) who had both visceral disease and progression on previous (neo)adjuvant ET received ET as initial treatment, most of which were single-agent ET.

**Initial first-line treatment regimens**

Of all the 1,877 patients, 1,215 patients (64.7%) received CT, while 662 patients (35.3%) received ET (Figure 1). The proportions of patients who received CT or ET as first-line treatment changed over the assessed periods (Figure 2A). Overall, the proportion of CT as initial first-line treatment decreased from 74.6% in 1996–2005 to 55.4% in 2016–2018, while the proportion of ET increased from 25.4% to 44.6%.

Among first-line CT (n=1,215), taxane-based regimen accounted for 66% (n=803), then vinorelbine-based, single-agent capecitabine, gemcitabine-based regimens accounted for 14.4% (n=175), 7.5% (n=91), 6.8% (n=83), respectively (Figure 2B). The use of anthracycline-based regimens decreased after 2010 (Figure S2). Aromatase inhibitors (AIs) were the most commonly used ET, accounting for 69% (n=457) of all first-line ET (n=662). Our data showed there was a decrease in AIs use after 2010, with a corresponding increase in fulvestrant use. A total of 53 patients received ET plus targeted drugs as first-line treatment since 2012 (Figure 2C, Figure S2).

**Outcomes of initial CT and ET**

The median follow-up time was 36 months (range, 12–220 months). In the CT group, 421 patients (34.7%) continued the initial CT regimen until disease progression, while 714 (58.8%) discontinued due to adverse events or other non-disease progression reasons. Among the latter group (n=714), 100 patients switched to other CT regimens, and 542 patients switched to endocrine drugs as maintenance therapy. In the ET group, only 24 patients (3.6%) discontinued due to non-disease progression reasons, among them 12 patients switched to other endocrine drugs, and 4 patients switched to chemotherapy (Table 4).

Of all patients, 10 patients died during the initial treatment.
or within 1 month after completion of initial treatment, among which 6 patients received CT and 4 patients received ET. Among them, 2 cases were primarily related to adverse events of combination of two chemotherapy drugs, 7 cases were associated with rapid disease progression, and 1 case died of unknown cause.

Discussion

This multicenter real-world study focused on initial systemic therapy, providing a comprehensive and updated picture of the first-line treatment in Chinese patients with HR-positive HER2-negative MBC. Our results demonstrated that the proportion of ET recommended as the preferred treatment by international and domestic guidelines increased from 25.4% to 44.6% in the past two decades. Moreover, we found that 322 patients (17.2% of the total patients) who had neither visceral metastasis nor progression on (neo)adjuvant ET wrongly received CT instead of ET, which is against the CSCO BC guideline.

Our study described the basic characteristics of patients with HR+/HER2– MBC and actual first-line treatment received. The age at first diagnosis of MBC in our study was about 10 years younger, and the tumor burden was heavier than that reported from European and American countries (15-20). We found that the proportion of patients who were chosen for CT as initial treatment was higher than that of ET. However, it is gratifying that the application of ET has increased gradually. Insufficient evidence supporting ET use, the unavailability of endocrine drugs 10 years ago, and the old concept held by some clinicians that CT is more effective than ET may have contributed to the high

Table 2 Characteristics influencing CT and ET prescription in first-line treatment for patients with HR+/HER2– MBC (CT vs ET, OR <1 preferred ET, OR >1 preferred CT)

|                                      | Univariate                  | Multivariate               |
|--------------------------------------|-----------------------------|----------------------------|
|                                      | OR (95% CI) | P value | OR (95% CI) | P value |
| Age group ≥60 y (Ref: <60 y)         | 0.507 (0.392, 0.656) | <0.0001 | 0.435 (0.326, 0.582) | <0.0001 |
| Comorbidity (Ref: no)                | 0.754 (0.601, 0.945) | 0.0143 | 0.784 (0.608, 1.011) | 0.0605 |
| HR status ER+/PR+ (Ref: ER+ or PR+)  | 0.475 (0.373, 0.606) | <0.0001 | 0.472 (0.364, 0.611) | <0.0001 |
| De novo stage IV (Ref: recurrent metastasis) | 4.901 (3.195, 7.518) | <0.0001 | 3.532 (2.141, 5.826) | <0.0001 |
| DRFI ≥24 m (Ref: <24 m)              | 0.505 (0.410, 0.622) | <0.0001 | 0.729 (0.571, 0.932) | 0.0115 |
| Progression on (neo)adjuvant ET a (Ref: no) | 0.592 (0.489, 0.718) | <0.0001 | 0.699 (0.562, 0.869) | 0.0012 |
| Metastatic sites ≥2 (Ref: 1)         | 1.910 (1.576, 2.316) | <0.0001 | 1.129 (0.879, 1.450) | 0.3411 |
| Visceral disease (Ref: no)           | 1.722 (1.421, 2.087) | <0.0001 | 0.700 (0.424, 1.157) | 0.1644 |
| Bone metastasis only (Ref: no)       | 0.379 (0.302, 0.476) | <0.0001 | 0.459 (0.340, 0.621) | <0.0001 |
| Liver metastasis (Ref: no)           | 2.167 (1.666, 2.818) | <0.0001 | 2.443 (1.561, 3.823) | <0.0001 |
| Lung metastasis (Ref: no)            | 1.392 (1.132, 1.712) | 0.0017 | 1.617 (1.017, 2.569) | 0.0421 |

a, progression on (neo)adjuvant ET was defined as prior (neo)adjuvant ET disease-free interval ≤12 months. OR, odds ratio; CI, confidence interval.

Table 3 The proportion of initial CT and ET in HR+/HER2– MBC patients with different clinical characteristics

| Visceral disease | Non-visceral disease |
|------------------|----------------------|
|                  | Progression on (neo)adjuvant ET | Non-progression on (neo)adjuvant ET | Progression on (neo)adjuvant ET | Non-progression on (neo)adjuvant ET |
| CT               | 318 (16.9%) | 328 (17.5%) | 243 (12.9%) | 322 (17.2%) |
| ET               | 146 (7.8%)  | 116 (6.2%)  | 246 (13.1%) | 153 (8.2%)  |

(Neo)adjuvant ET information was missing in 5 patients.
Figure 2 The CT and ET regimens as initial first-line treatment in patients with HR+/HER2– MBC. (A) Proportions of CT and ET as first-line treatment in different years (n=1,877); (B) CT regimens as initial first-line treatment (n=1,215). (C) ET regimens as initial first-line treatment (n=662). T-based: single-agent taxane (T), TX, TP, GT, AT/TAC, and taxanes plus bevacizumab (T + Bev); N-based: single-agent vinorelbine, NX, NP; Cap: single-agent capcitabine; G-based: single-agent gemcitabine, GP, gemcitabine combined with capcitabine; A/E based: single-agent anthraccline (A/E), AC; Others: etoposide, 5-FU; AI: aromatase inhibitors; FUL: fulvestrant; ET+ targeted drugs: endocrine therapy combined with targeted drugs, including CDK4/6 inhibitors, everolimus, and tucidinostat; TAM/TOR: tamoxifen, toremifene; MPA: megestrol, medroxyprogesterone.
proportion of CT use. Another cause could be the time taken to promote the recommended guidelines amongst the community widely. In addition, younger age and heavier tumor burden may further explain the high proportion of CT observed in our study.

Several factors may have contributed to the increased proportion of ET applications over the observed period. CT was reported with similar effect on survival as ET, accompanied by more adverse events (21,22). Outdated concepts are slowly changing due to powerful evidence from RCTs supporting ET use and the strong recommendations of guidelines. More importantly, ET agents have been broadly available. Fulvestrant was first approved for use in China in 2011, followed by the application of targeted drugs, such as everolimus (10), CDK4/6 inhibitors (11-13), and tucidinostat (14). Besides, the fact that clinicians strive to improve the quality of life of MBC patients, which is hard to achieve with CT, may also account for increased ET use since 2010 observed in our study.

As recommended by international (5-7) and CSCO BC guidelines, progression on prior ET and visceral disease, especially visceral crisis, are key factors when making therapeutic decisions for patients with HR+/HER2– MBC. Our study revealed 322 patients (17.2% of total patients) in the CT group exhibiting neither visceral metastasis nor progression on (neo)adjuvant ET and instead should have received ET, according to the guidelines. For patients with bone metastasis only and without proof of ET resistance, RCTs showed that the progression free survival (PFS) of single-agent ET was 16.8–22.3 months (23,24). This means the use of CT would make patients suffer unnecessary toxicity and inconvenience from excessive treatment. Furthermore, we found that 146 patients (7.8% of total patients) with both visceral metastasis and progression on prior ET received ET as first-line treatment, most of which were single-agent ET. According to RCT results, the median PFS of single-agent ET in patients with progression on prior ET was less than 6 months (10,14,25). For these patients, ET combined with targeted drugs is recommended as the preferred option (5,8,10,14,25-27), CT may also be considered. The speed of disease progression is another important factor when making therapeutic decisions (6), but it has not been clearly defined in both international and domestic guidelines,
which may lead to confusion in recommending treatment options.

Our study revealed unreasonable first-line treatment of HR+/HER2– MBC, including over-treatment and undertreatment, highlighting the need for greater promotion of adherence to current guidelines. Based on these data, the clinical application for ET should be appropriately expanded in first-line treatment. For patients without visceral disease and proof of endocrine resistance, ET (including ET combined with targeted drugs) is the preferred regimen. For patients with progression on prior ET, combination of ET and targeted drugs is recommended as the preferred option, even in the presence of visceral disease. CT is appropriate for those diseases requiring rapid remission, such as visceral crisis or rapidly progressive diseases, based on full assessment of potential benefits and toxicity.

Treatment recommendations for systemic therapy in MBC should be made on an individual basis, taking into account the age, physical conditions, clinical and pathological features of patients. In addition, adverse reactions, costs, and convenience of treatment also need to be considered. Our study showed that MBC patients with age ≥60 y, ER+/PR+, DRFI ≥24 months and bone metastasis only, were preferably chosen for ET as first-line treatment, which is mainly due to RCTs showing that patients with these characteristics are more likely to benefit from ET (23,28-30). Surprisingly, patients with progression on (neo)adjuvant ET tended to choose ET as first-line treatment in our study. In fact, most of those patients showed secondary resistance to previous ET, and only a small number showed primary resistance. Patients with de novo stage IV, liver or lung metastasis tended to receive CT because these factors predict poor prognosis and require rapid response.

Taxane-based regimens were the main CT regimens, while AIs were the main ET regimens. In patients receiving ET, the proportion of single-agent fulvestrant and ET plus targeted drugs increased, although only slightly, mainly because fulvestrant and targeted drugs were not covered under Medicare payment at that period.

In our study, 58.8% of patients (n=714) in CT group discontinued the initial CT regimen due to non-disease progression reasons, including adverse events, completion of planned treatment, and personal reasons of patients (probably cost and inconvenience). Most of these patients switched to endocrine drugs as maintenance therapy. These results showed that CT was associated with more adverse events, lower quality of life, leading to a higher rate of drug withdrawal, while ET was associated with less toxicity and better adherence, which is more likely to be chosen as maintenance therapy.

Inherent to the retrospective nature of observational cohort studies, our study has several limitations. No quality of life and details of adverse events were available. Although guidelines strongly recommend ET combined with targeted therapy as first-line treatment, there were only a small number of cases in our study, possibly because of the high cost, which is likely to affect the application of ET.

Conclusions

We made a deep descriptive analysis of baseline characteristics and actual first-line treatment received in Chinese patients with HR+/HER2– MBC. We demonstrated the advances and inappropriate treatments that had been inconsistent with guidelines across the past two decades. These results may provide data to promote guideline adherence in first-line treatment of HR+/HER2– MBC. The clinical application for ET should be appropriately expanded in first-line treatment, especially for patients without visceral disease and proof of endocrine resistance (Research number: CSCO BC RWS2101).

Acknowledgments

We thank our colleagues at The Fifth Medical Centre of Chinese PLA General Hospital, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Jiangsu Province Hospital & The First Affiliated Hospital of Nanjing Medical University, The Affiliated Hospital of Qingdao University for their support and assistance. We would like to thank all patients and their family members for supporting our study. In addition, we thank the AME English Language editor J. Chapnick and B. Draper. Funding: This study was supported by research and development project of medical data and artificial intelligence in Chinese PLA General Hospital (Grant number 2019MBD-056).

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/atm-20-8252

Data Sharing Statement: Available at http://dx.doi.org/10.21037/atm-20-8252
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-8252). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics board of The Affiliated Hospital of Qingdao University (No. 221311920). Because of the retrospective nature of the research, the requirement for informed consent was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
1. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol 2014;15:e279-89.
2. Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24 Suppl 2:S26-35.
3. Chia SK, Speers CH, D’Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9.
4. Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:3307-29.
5. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol 2018;29:1634-57.
6. Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016;34:3069-103.
7. Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18:452-78.
8. Xu F, Jiang Z. CSCO BC guideline: updates for hormone receptor-positive breast cancer in 2020. Transl Breast Cancer Res 2020;1:3.
9. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5.
10. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
11. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016;375:1925-36.
12. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016;375:1738-48.
13. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017;35:3638-46.
14. Jiang Z, Li W, Hu X, et al. Tucatinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:806-15.
15. Jacquet E, Lardy-Cléaud A, Pistilli B, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 2018;95:93-101.
16. Bonotto M, Gerratana L, Di Maio M, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Breast 2017;31:114-20.
17. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 2016;27:256-62.
18. Twelves C, Cheeseman S, Sopwith W, et al. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer.
retrospective analysis from Leeds Cancer Centre. BMC Cancer 2020;20:53.
19. Fietz T, Tesch H, Rauh J, et al. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study. Breast 2017;34:122-30.
20. Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin 2014;30:1537-45.
21. Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res 2014;14:929-40.
22. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003:CD002747.
23. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016;388:2997-3005.
24. Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 2018;29:669-80.
25. Turner NC, Ro J, André F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015;373:209-19.
26. Sledge GW Jr, Tai M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2–Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017;35:2875-84.
27. Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol 2019;20:1360-9.
28. Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019;20:1750-9.
29. Jin L, Chen K, Tan C, et al. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist 2020;25:e1170-80.
30. Cristofanilli M. Metastatic breast cancer: focus on endocrine sensitivity. Lancet 2016;388:2961-2.

(English Language Editors: J. Chapnick and B. Draper)